## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

ABN	
37 160 986 201	
We (the entity) give ASX the following	g information.
Part 1 - All issues You must complete the relevant sections (attack)	
+Class of +securities issued or to be issued	Fully paid ordinary shares (" <b>Shares</b> ").

Name of entity

Estia Health Limited

<sup>+</sup> See chapter 19 for defined terms.

Number of \*securities issued or to be issued (if known) or maximum number which may be issued 65,153,096 Shares pursuant to the entitlement offer detailed in the announcement dated 12 December 2016 ("Entitlement Offer").

This total comprises 33,284,751 Shares issued under the institutional component of the Entitlement Offer and 31,868,345 Shares issued under the retail component of the Entitlement Offer.

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares issued for cash consideration.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes.
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	\$2.10
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The purpose of the Entitlement Offer was to raise funds to reduce core debt, provide additional balance sheet strength and give Estia the flexibility to execute its conservative business plan and growth agenda.
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?	N/A
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6с	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	N/A
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	The issue date for Shares under the institutional component of the Entitlement Offer was 21 December 2016.

January 2017.

Cross reference: item 33 of Appendix 3B.

The issue date for Shares under the retail

component of the Entitlement Offer is 19

8	Number	and	+class	of	all
	+securities	quo	oted o	n A	ASX
	(including	the	+secur	ities	in
	section 2 if	fappli	cable)		

Number	+Class
260,602,749	Fully paid ordinary shares

Number and +class of all 9 +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
N/A	N/A

Dividend policy (in the case of a 10 trust, distribution policy) on the increased capital (interests)

Refer to the announcement dated 12 December 2016.

### Part 2 - Pro rata issue

11	Is	security	holder	approval
	req	uired?		

No.

Is the issue renounceable or non-12 renounceable?

Non-renounceable.

13 will be offered

Ratio in which the \*securities | 1 new Share for every 3 Shares held.

<sup>+</sup>Class of <sup>+</sup>securities to which the | Fully paid ordinary shares. 14 offer relates

<sup>+</sup>Record date to determine 15 entitlements

7.00pm (AEDT) on 14 December 2016.

16 Will holdings different on registers (or subregisters) be aggregated for calculating entitlements?

No.

<sup>+</sup> See chapter 19 for defined terms.

17 Policy for deciding entitlements in relation to fractions

Where fractions arose in the calculation of shareholders' entitlements under the Entitlement Offer, they were rounded up to the nearest whole number.

Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

19 Closing date for receipt of acceptances or renunciations

For the retail component of the Entitlement Offer, all countries other than Australia and New Zealand.

For the institutional component of the Entitlement Offer, refer to the investor presentation dated 12 December 2016.

The institutional component of the Entitlement Offer closed on 12 December 2016.

The retail component of the Entitlement Offer closed on 11 January 2017.

20	Names of any underwriters	Macquarie Capital (Australia) Limited ("MCAL").
21	Amount of any underwriting fee or commission	The Company has agreed to pay MCAL the following fees:  • an underwriting fee of 3% of the institutional Entitlement Offer component;  • an underwriting fee of 3% of the retail Entitlement Offer component; and  • a management fee of 0.75% of the institutional Entitlement Offer component; and  • a management fee of 0.75% of the retail Entitlement Offer component.  These fees are expected to equal approximately \$5 million.
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	No prospectus was produced. Retail Information Booklets and personalised Entitlement and Acceptance Forms were sent to eligible retail shareholders on 19 December 2016. An investor presentation was provided to the ASX on 12 December 2016.

Limited

04/03/2013 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
3 <del>2</del>	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	The issue date for Shares under the institutional component of the Entitlement Offer was 21 December 2016.
		The issue date for Shares under the retail component of the Entitlement Offer is 19 January 2017.
	t 3 - Quotation of sec	
34	Type of *securities (tick one)	
(a)	*Securities described in Part	:1
(b)	-	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible

## Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to docum	o indicate you are providing the information nents	on or
35		securities, the names of the 20 largest holders of the number and percentage of additional *securities
36		securities, a distribution schedule of the additional mber of holders in the categories
37	A copy of any trust deed for the	he additional <sup>+</sup> securities
Enti	ties that have ticked box 34	<b>1</b> (b)
38	Number of *securities for which *quotation is sought	N/A
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	N/A
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest	
	payment	

04/03/2013 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

41	Reason for request for quotation	N/A
	now	
	Example: In the case of restricted securities, end of restriction period	
	(if issued upon conversion of another *security, clearly identify that other *security)	

42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Number	+Class
N/A	N/A

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.

- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

	== == == == ==			
Print name:	Suzy Watson			
2010	Company secretary			
Sign here: 2016		Date:	21	December

04/03/2013 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.